Short-term bearish pressure expected on dilution fears typical of a post-effective micro-cap shelf. Traders should monitor for an 8-K or prospectus supplement (pricing announcement) — especially since the cross-filing actuarial data marks this effect-ipo-context + effect-shelf-context combo as an amplifier, suggesting heightened propensity to tap the shelf quickly. If the company draws the shelf at a large discount to market, expect 20-40% downside. Conversely, if no offering occurs within 30 days, bearish overhang may partially fade.
Price Chart
Executive Summary
Scinai Immunotherapeutics' shelf registration on Form F-3 (File No. 333-295698) was declared effective by the SEC on May 19, 2026. This allows the company to offer and sell securities (equity, debt, or other instruments) from time to time at its discretion. For a micro-cap biotech with a $2M market cap, this creates a tangible dilution overhang and signals potential near-term capital-raising activity.
Key Facts
- Effectiveness date: May 19, 2026
- Form F-3 shelf registration (File No. 333-295698) covering unspecified securities
- Company market cap is approximately $2M; minimal absolute dollar offering could cause significant dilution
- Company has no disclosed revenue or pipeline revenue milestones in this filing
Financial Impact
Potential dilutive offering; exact size undisclosed but at $2M market cap, even a small $500K-$1M raise could dilute existing shareholders by 20-50%
Risk Factors
- Immediate dilution risk if shelf is drawn down quickly
- Micro-cap biotech with no disclosed revenue may face severe adverse selection in equity markets
- Cross-filing amplifier verdict suggests historically elevated odds of near-term capital raise after shelf effectiveness
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-001706 |
| Document: 9999999995-26-001706-index.html | 9999999995-26-001706 |
| Document: 9999999995-26-001706.txt | 9999999995-26-001706 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | 6-K | $0.6813 | awaiting T+60 | — | $0.5301 (−22.19%) |
Oct 16, 2026 11d ago | 6-K | $0.7520 | awaiting T+60 | — | $0.5301 (+29.51%) |
Oct 16, 2026 11d ago | Press Release | $0.7524 | awaiting T+60 | — | $0.5301 (+29.55%) |
Oct 15, 2026 12d ago | 6-K | $0.9015 | awaiting T+60 | — | $0.5301 (+41.20%) |
Oct 13, 2026 14d ago | 6-K | $1.23 | awaiting T+60 | — | $0.5301 (−56.90%) |
Oct 6, 2026 21d ago | EFFECT | $1.22 | awaiting T+60 | — | $0.5301 (+56.55%) |
Sep 21, 2026 5w ago | 6-K | $1.69 | awaiting T+60 | — | $0.5301 (−68.63%) |
Aug 26, 2026 8w ago | 6-K | $2.87 | awaiting T+60 | — | $0.5301 (+81.53%) |
Aug 19, 2026 9w ago | 6-K | $0.2740 | awaiting T+60 | — | $0.5301 (−93.47%) |
Jun 17, 2026 18w ago | 6-K | $0.3370 $0.2440 | ▼ −27.60% | ▼ −30.28% | $0.5301 (+57.30%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers